EP3838287A3 - Compounds and methods of promoting myelination - Google Patents

Compounds and methods of promoting myelination Download PDF

Info

Publication number
EP3838287A3
EP3838287A3 EP20201358.7A EP20201358A EP3838287A3 EP 3838287 A3 EP3838287 A3 EP 3838287A3 EP 20201358 A EP20201358 A EP 20201358A EP 3838287 A3 EP3838287 A3 EP 3838287A3
Authority
EP
European Patent Office
Prior art keywords
compounds
methods
promoting myelination
promoting
precursor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20201358.7A
Other languages
German (de)
French (fr)
Other versions
EP3838287A2 (en
Inventor
Paul TESAR
Drew Adams
Zita HUBLER
Matthew ELITT
Dharmaraja ALLIMUTHU
Steven B Landau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Original Assignee
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University filed Critical Case Western Reserve University
Publication of EP3838287A2 publication Critical patent/EP3838287A2/en
Publication of EP3838287A3 publication Critical patent/EP3838287A3/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)

Abstract

A method of promoting the generation of oligodendrocytes from oligodendrocyte precursor cells by enhancing their survival and/or maturation includes administering to the cell an effective amount of an agent that enhances and/or induces accumulation of Δ8,9-unsaturated sterol intermediates of the cholesterol biosynthesis pathway in the oligodendrocyte precursor cells.
EP20201358.7A 2016-07-27 2017-07-27 Compounds and methods of promoting myelination Pending EP3838287A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662367416P 2016-07-27 2016-07-27
US201762452204P 2017-01-30 2017-01-30
EP17835280.3A EP3490556A4 (en) 2016-07-27 2017-07-27 Compounds and methods of promoting myelination
PCT/US2017/044205 WO2018022904A2 (en) 2016-07-27 2017-07-27 Compounds and methods of promoting myelination

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP17835280.3A Division EP3490556A4 (en) 2016-07-27 2017-07-27 Compounds and methods of promoting myelination

Publications (2)

Publication Number Publication Date
EP3838287A2 EP3838287A2 (en) 2021-06-23
EP3838287A3 true EP3838287A3 (en) 2021-07-28

Family

ID=61017363

Family Applications (2)

Application Number Title Priority Date Filing Date
EP17835280.3A Withdrawn EP3490556A4 (en) 2016-07-27 2017-07-27 Compounds and methods of promoting myelination
EP20201358.7A Pending EP3838287A3 (en) 2016-07-27 2017-07-27 Compounds and methods of promoting myelination

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP17835280.3A Withdrawn EP3490556A4 (en) 2016-07-27 2017-07-27 Compounds and methods of promoting myelination

Country Status (7)

Country Link
US (3) US11344511B2 (en)
EP (2) EP3490556A4 (en)
JP (2) JP7325104B2 (en)
CN (2) CN109789128A (en)
CA (1) CA3031818A1 (en)
MA (2) MA45793A (en)
WO (1) WO2018022904A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3490556A4 (en) 2016-07-27 2020-04-15 Case Western Reserve University Compounds and methods of promoting myelination
EP3496725B1 (en) * 2016-08-12 2022-10-05 The Regents of The University of California Remyelination therapies
CN109512817A (en) * 2017-09-20 2019-03-26 中国人民解放军陆军总医院 The pharmaceutical applications of clemastine or combinations thereof object
WO2019126702A1 (en) * 2017-12-22 2019-06-27 Case Western Reserve University Compounds for promoting myelination
EP3781674A1 (en) * 2018-04-17 2021-02-24 Case Western Reserve University Induction of myelinating oligodendrocytes in human cortical spheroids
US12102644B2 (en) 2018-04-17 2024-10-01 Case Western Reserve University Compounds and methods of promoting myelination
JP2022036341A (en) * 2018-10-12 2022-03-08 学校法人慶應義塾 Pharmaceutical composition for treating chronic dermatitis
US20220024851A1 (en) * 2018-12-03 2022-01-27 Convelo Therapeutics, Inc. Crystalline forms of multicyclic compounds and uses thereof
EP3797769A1 (en) 2019-09-25 2021-03-31 Fontès, M. Michel Composition for therapeutic use
EP3831369A1 (en) * 2019-12-03 2021-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Squalene for the treatment of demyelinating disorders
JP2021143141A (en) * 2020-03-11 2021-09-24 花王株式会社 Regulatory t-cell inducer
CN111440771A (en) * 2020-03-17 2020-07-24 中山大学附属第三医院 C L CN2 homozygous mutation-containing white matter encephalopathy patient specific induced pluripotent stem cell line
CN115667503A (en) * 2020-05-01 2023-01-31 儿童医疗中心有限公司 Compositions and methods for promoting myelination
KR102657342B1 (en) * 2020-05-20 2024-04-15 고려대학교 산학협력단 Method for producing organoids comprising oligodendrocytes from human pre-OPCs specialized for differentiation into oligodendrocytes, organoids prepared by the above method and use thereof
US20230181554A1 (en) * 2020-05-25 2023-06-15 Ono Pharmaceutical Co., Ltd. Agent for protecting and/or regenerating neuromuscular junction
US20240167030A1 (en) * 2021-04-02 2024-05-23 Case Western Reserve University Methods and compositions for accelerating oligodendrocyte maturation
CN113584041A (en) * 2021-04-15 2021-11-02 浙江警察学院 Construction method of transgenic zebra fish (mbp: egfp) spinal cord disease model
CN115501234B (en) * 2021-08-02 2023-08-08 中山大学·深圳 Application of compound in preparing medicine for preventing and treating demyelinating diseases
CN113603732B (en) * 2021-08-25 2024-02-13 江南大学 Non-animal chondroitin sulfate oligosaccharide and preparation method thereof
CN114651787A (en) * 2022-04-21 2022-06-24 贵州医科大学附属医院 Construction method and application of mouse for constructing mouse optic nerve specific demyelination model
WO2023225190A1 (en) * 2022-05-18 2023-11-23 The Scripps Research Institute Method for synergistic enhancement of remyelination via modulation of rxr and a heterodimeric partner
TW202409039A (en) * 2022-07-15 2024-03-01 美商百健Ｍａ公司 Emopamil-binding protein inhibitors and uses thereof
WO2024073658A1 (en) * 2022-09-30 2024-04-04 Genentech, Inc. Hydantoin modulators of cholesterol biosynthesis and their use for promoting remyelination

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124131A1 (en) * 2007-04-05 2008-10-16 The John Hopkins University Antifungal agents as neuroprotectants

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
FR2641276B1 (en) 1988-12-30 1991-07-12 Sanofi Sa BENZENE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE69534629D1 (en) 1994-01-18 2005-12-29 Scripps Research Inst DERIVATIVES OF ZINC FINGER PROTEINS AND METHODS
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
USRE39229E1 (en) 1994-08-20 2006-08-08 Gendaq Limited Binding proteins for recognition of DNA
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
KR20000021073A (en) 1998-09-25 2000-04-15 박원배 Inhibitors for biosynthesis of cholesterol
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
GB9824207D0 (en) * 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
KR20000042507A (en) 1998-12-21 2000-07-15 박원배 5.,6-dihydrodibenzo(a,g)quinolizinium derivative having inhibition effect on bio-synthesis of cholesterol
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
FR2794742B1 (en) 1999-06-11 2005-06-03 Sanofi Synthelabo NOVEL BENZENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
WO2001077350A2 (en) 2000-04-07 2001-10-18 Large Scale Biology Corporation Compositions and methods for inhibiting gene expression
WO2001088197A2 (en) 2000-05-16 2001-11-22 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
JP2002060786A (en) 2000-08-23 2002-02-26 Kao Corp Germicidal stainproofing agent for hard surface
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
JP2005500061A (en) 2001-08-20 2005-01-06 ザ スクリップス リサーチ インスティテュート Zinc finger binding domain for CNN
EP1546105A1 (en) 2002-07-17 2005-06-29 Lek Pharmaceutical and Chemical Co. D.D. Novel derivatives of pyridylethanol (phenylethyl) amines as inhibitors of cholesterol biosynthesis, processes for their preparation, and pharmaceutical compositions containing them
CA2607598A1 (en) 2005-06-06 2006-12-14 University Of South Florida Treatment with sigma receptor agonists post-stroke
US20080089861A1 (en) 2006-07-10 2008-04-17 Went Gregory T Combination therapy for treatment of demyelinating conditions
WO2008021970A2 (en) * 2006-08-09 2008-02-21 Reid William K Treatment of motor neuron disease, including certain neurological disorders, motor neuropathies and chronic inflammatory diseases
US8585526B2 (en) 2007-06-18 2013-11-19 American Axle & Manufacturing, Inc. Vehicle driveline component having heat sink for increased heat rejection capabilities
US20100009970A1 (en) * 2008-03-19 2010-01-14 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010021681A2 (en) 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US20100183613A1 (en) * 2008-10-22 2010-07-22 Novartis Ag Methods of using mevalonate decarboxylase (mvd) antagonists
EP3156062A1 (en) 2010-05-17 2017-04-19 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
EP3044218B1 (en) * 2013-09-10 2020-05-27 Board Of Regents Of the University Of Texas System Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins
WO2015088625A2 (en) * 2013-09-25 2015-06-18 Case Western Reserve University Compounds and methods of promoting myelination
WO2015048306A1 (en) * 2013-09-26 2015-04-02 The Scripps Research Institute Novel agents targeting cyp51
WO2015143072A1 (en) * 2014-03-18 2015-09-24 Whitehead Institute For Biomedical Research Methods for inhibiting proliferation of cancer cells and uses thereof
US10082496B2 (en) * 2014-09-10 2018-09-25 Board Of Regents Of The University Of Texas System Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
EP3490556A4 (en) 2016-07-27 2020-04-15 Case Western Reserve University Compounds and methods of promoting myelination
WO2019126702A1 (en) 2017-12-22 2019-06-27 Case Western Reserve University Compounds for promoting myelination

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124131A1 (en) * 2007-04-05 2008-10-16 The John Hopkins University Antifungal agents as neuroprotectants

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUGGENBERGER ET AL: "Functional analysis of cholesterol biosynthesis by RNA interference", JOURNAL OF STEROID BIOCHEMISTRY & MOLECULAR BIOLOGY, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 104, no. 3-5, 1 May 2007 (2007-05-01), pages 105 - 109, XP022113856, ISSN: 0960-0760, DOI: 10.1016/J.JSBMB.2007.03.001 *
WANG CHAO ET AL: "Reducing CYP51 inhibits follicle-stimulating hormone induced resumption of mouse oocyte meiosis in vitro", JOURNAL OF LIPID RESEARCH, vol. 50, no. 11, 1 November 2009 (2009-11-01), US, pages 2164 - 2172, XP055812691, ISSN: 0022-2275, DOI: 10.1194/jlr.M800533-JLR200 *
XU BAOSHAN ET AL: "Silencing of mouse hepatic lanosterol 14-alpha demethylase down-regulated plasma low-density lipoprotein cholesterol levels by short-term treatment of siRNA", BIOLOGICAL & PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 31, no. 6, 1 June 2008 (2008-06-01), pages 1182 - 1191, XP002546932, ISSN: 0918-6158, DOI: 10.1248/BPB.31.1182 *

Also Published As

Publication number Publication date
US11344511B2 (en) 2022-05-31
US20180228743A1 (en) 2018-08-16
EP3490556A2 (en) 2019-06-05
WO2018022904A3 (en) 2019-02-14
WO2018022904A2 (en) 2018-02-01
MA53246A (en) 2021-07-28
CA3031818A1 (en) 2018-02-01
CN114652735A (en) 2022-06-24
CN109789128A (en) 2019-05-21
JP2023139105A (en) 2023-10-03
US20190269670A1 (en) 2019-09-05
EP3490556A4 (en) 2020-04-15
US20230000798A1 (en) 2023-01-05
JP7325104B2 (en) 2023-08-14
EP3838287A2 (en) 2021-06-23
JP2019525938A (en) 2019-09-12
MA45793A (en) 2021-03-24

Similar Documents

Publication Publication Date Title
EP3838287A3 (en) Compounds and methods of promoting myelination
AU2020201465A1 (en) Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing
MX2019001253A (en) Protein-active agent conjugates and method for preparing the same.
EP2670852A4 (en) Microorganisms and methods for the biosynthesis of butadiene
PH12018500452A1 (en) Novel modulators and methods of use
WO2013006474A3 (en) Requlatora t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127
WO2012056457A3 (en) Compositions and methods for activating expression by a specific endogenous mirna
MX342856B (en) Methods and compositions for weed control.
MX367859B (en) Methods and materials for biosynthesis of mogroside compounds.
SG10201808661XA (en) Method of treating obesity using antioxidant inflammation modulators
WO2009047644A3 (en) Method of treating vitamin d insufficiency and deficiency
WO2012168410A3 (en) Methods for treating lignocellulosic material
AU2012249851A8 (en) MicroRNA compounds and methods for modulating miR-21 activity
EP3540069A3 (en) Biosynthetic pathways and products
WO2011160052A3 (en) Methods and compositions for sequence specific rna endonucleases
MX336320B (en) Non-dairy beverage composition.
IL231787A0 (en) Uridine diphosphate derivatives ,compositions and methods for treating neurodegenerative disorders
IN2012DN03242A (en)
MX2013013649A (en) Quinone compounds for treating ape1 mediated diseases.
EP2735612A4 (en) Mutant b-glucosidase, enzyme composition for decomposing biomass, and method for producing sugar solution
WO2013038269A3 (en) Apparatus and methods for treating sugarcane stem cuttings
MX352837B (en) Method for labeling intracellular and extracellular targets of leukocytes.
WO2012056449A3 (en) Compositions and methods for specific cleavage of exogenous rna in a cell
WO2012021678A3 (en) Isolated bacteria, methods for use, and methods for isolation
GB2507700A (en) Compositions and methods for treatment of metastatic cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201013

AC Divisional application: reference to earlier application

Ref document number: 3490556

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/16 20060101AFI20210618BHEP

Ipc: A61K 38/21 20060101ALI20210618BHEP

Ipc: A61P 25/28 20060101ALI20210618BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230522

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230901